A 3H-flunitrazepam binding inhibitor is present in psychiatric patients' sera.
We investigated the possible existence of endogenous compounds acting on benzodiazepine central receptors in the serum of patients with panic attacks or depression. Our results show the presence of a substance which inhibits the 3H-flunitrazepam binding specifically in the samples taken from the patients' groups, and which is not present in normal controls, in the range of concentrations used. This compound has a molecular weight below 1,000 daltons, is heat-stable, and resistant to proteolytic degradation. The demonstration of this inhibitor opens new perspectives in the study of the biochemistry of anxiety.
Marazziti
D
D
Institute of Psychiatric Clinic, University of Pisa, Italy.
Pietrini
P
P
Martini
C
C
Giannaccini
G
G
Perugi
G
G
Placidi
G F
GF
Cassano
G B
GB
Lucacchini
A
A
D000293:Adolescent; D000328:Adult; D000379:Agoraphobia / Q000097:blood*; D000818:Animals; D001921:Brain / Q000378:metabolism; D002417:Cattle; D003866:Depressive Disorder / Q000097:blood*; D005239:Fear / Q000502:physiology*; D005260:Female; D005445:Flunitrazepam / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010200:Panic / Q000502:physiology*; D010698:Phobic Disorders / Q000097:blood*; D011963:Receptors, GABA-A / Q000378:metabolism*; D012008:Recurrence
D011963:Receptors, GABA-A; D005445:Flunitrazepam